Retrospective Study

Ovarian teratoma related anti-N-methyl-D-aspartate receptor encephalitis: A case series and review of the literature

Shan-Ji Li, Min-Hua Yu, Jie Cheng, Wen-Xin Bai, Wen Di

Specialty type: Obstetrics and gynecology

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification
Grade A (Excellent):  A
Grade B (Very good):  0
Grade C (Good): 0
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Solanki SL, India

Received: July 12, 2021
Peer-review started: July 12, 2021
First decision: July 26, 2021
Revised: August 15, 2021
Accepted: April 9, 2022
Article in press: April 9, 2022
Published online: June 6, 2022

Abstract

BACKGROUND
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a rare but important complication of ovarian teratoma. Between July 2012 and December 2019, six patients with ovarian teratoma-associated anti-NMDAR encephalitis were enrolled in our hospital and their clinical characteristics, treatment, and follow-up were reviewed. We also conducted a systematic literature review of ovarian teratoma related anti-NMDAR encephalitis reports between January 2014 and December 2019.

AIM
To better understand anti-NMDAR encephalitis through literature review and patients enrolled in our hospital.

METHODS
The six patients enrolled in the study were those diagnosed with anti-NMDAR encephalitis. Their history, clinical manifestations, and medications were recorded and optimum treatment provided in addition to maintaining a record of the
follow-ups. In addition, we also extensively surveyed the literature and provide summarized data from 155 published cases of anti-NMDAR encephalitis from 130 case reports. PubMed and Scopus were the sources of these publications and the time period covered was 6 years ranging from January 2014 through December 2019.

RESULTS
The six patients enrolled for this study presented with typical symptoms resulting in a diagnosis of ovarian teratoma induced anti-NMDAR encephalitis. Appropriate interventions led to a positive outcome in all the patients, with five of six patients reporting full recovery and the sixth patient recovering with a few deficits. No death was recorded. The literature survey comprising of 155 patients cases across 130 case reports of anti-NMDAR encephalitis clearly indicated an upward trend in the reports/diagnosis in China, particularly in the surveyed time from 2014 through 2019. The majority of patients (150/155) underwent surgical intervention resulting in positive outcome. No treatment intervention was mentioned for one case while the four patients who were not surgically operated succumbed to the disease.

CONCLUSION
Suspected anti-NMDAR encephalitis should be quickly evaluated for anti-NMDAR antibodies since early diagnosis is important. In case of a tumor, its earliest and complete removal is recommended. Finally, early use of corticosteroids and IgG-depleting strategies (intravenous immunoglobulin or plasma exchange) may improve outcome.

Key Words: Ovarian teratoma; Anti-N-methyl-D-aspartate receptor encephalitis; Immunotherapy; Surgery

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: We describe our findings from six cases from our own hospital and, in addition, we review 155 cases reported in 130 case reports. We describe the symptoms, diagnosis, and treatment, as well as prognosis. Our results indicate the importance of an early and quick intervention through surgery and immunotherapy, failing which the condition can be fatal.

Citation: Li SJ, Yu MH, Cheng J, Bai WX, Di W. Ovarian teratoma related anti-N-methyl-D-aspartate receptor encephalitis: A case series and review of the literature. World J Clin Cases 2022; 10(16): 5196-5207
URL: https://www.wjgnet.com/2307-8960/full/v10/i16/5196.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i16.5196

INTRODUCTION
Encephalitis is a complex neurological syndrome that is caused by inflammation of the brain parenchyma[1]. The main causes of encephalitis include a range of infectivity and autoimmunity. Viruses are the most commonly identified pathogenic factors[1]. Autoimmune encephalitis (AE) has two major subtypes: (1) Classic paraneoplastic limbic encephalitis marked by well-characterized onconeural autoantibodies against intracellular neuronal antigens; and (2) new-type AE characterized by autoantibodies against neuronal surface or synaptic antigens[2]. N-methyl-D-aspartate receptor (NMDAR) encephalitis is a new-type AE[3-4], wherein antibodies attack N-methyl-D-aspartate (NMDA)-type glutamate receptors at central neuronal synapses[5]. Affected patients develop prominent psychiatric and behavioral symptoms, rapid memory loss, seizures, abnormal movements (dyskinesias), hypoventilation, and autonomic instability[6-8].

The first case of paraneoplastic encephalitis related to ovarian teratoma was described in 1997[9,10]. In 2005, a syndrome marked by psychiatric symptoms, memory deficits, hypoventilation, and decreased consciousness was reported in four young women with ovarian teratomas[11,12]. A severe form of encephalitis associated with antibodies against NR1-NR2 heteromers of the NMDAR was identified by Dalmau et al[6] in 2007. The target antigen was identified as the NMDAR, and the disorder named “anti-NMDAR encephalitis”; specific autoantibodies to the NMDAR were soon detected in these and eight other patients with similar neurological symptoms, seven of whom also had ovarian teratomas. Iizuka et al[8] confirmed the presence of NMDAR antibodies in four young women with ovarian teratoma and described the clinical course progression through five phases of anti-NMDAR encephalitis: Prodromal, psychotic, unresponsive, hyperkinetic, and gradual recovery.
Herpes simplex encephalitis (HSE) plays a vital role in triggering the synthesis of anti-NMDAR antibodies[13,14]. A study of 501 patients with anti-NMDAR encephalitis found that 38% of patients had concomitant tumors, most commonly ovarian teratomas. Other relatively rare neoplasms include extra-ovarian teratomas, testicular germ-cell tumors, small-cell lung cancer, and Hodgkin’s lymphoma[15]. From a cohort study of 577 patients with anti-NMDAR encephalitis, 220 patients (38%) had an underlying neoplasm, among which 207 tumors (94%) were ovarian teratomas[4]. A review of 432 cases of anti-NMDAR encephalitis revealed that of the 293 female patients, 68 (23%) had ovarian teratoma [16].

The first case of anti-NMDAR encephalitis with ovarian teratoma was reported in China in 2010[17]. A single-center prospective study that included patients with anti-NMDAR encephalitis with ovarian teratoma from 2011 to 2016 admitted to Peking Union Medical College Hospital, Beijing, discussed the clinical characteristics, treatment, and prognosis of the disease[18]. The association between ovarian teratoma and anti-NMDAR encephalitis is relatively unknown and most of the present studies on anti-NMDAR encephalitis with ovarian teratoma are case reports and systematic reviews. Here, we illustrate six cases of ovarian teratoma-related anti-NMDA receptor encephalitis, and also present the results of a systematic review and analysis of cases reported after 2013.

**MATERIALS AND METHODS**

**Case description**

Between July 2012 and December 2019, six patients with ovarian teratoma-associated anti-N-methyl-D-aspartate receptor encephalitis were enrolled in Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University. All patients’ data like clinical characteristics, treatment, and follow-up were reviewed. The study was approved by the Ethic Committee of Shanghai Jiao Tong University. Informed consent was obtained from all patients for participation in this study and the publication of results.

**Literature systematic review**

**Sources:** A comprehensive search of PubMed and Scopus was performed for all studies published prior from January 2014 to December 2019, using the search terms “encephalitis” and “teratoma”, which yielded 226 articles in PubMed and 344 in Scopus (Figure 1). A systematic review of these papers was performed, and after removal of repeated 165 articles from both searches, the full text of all articles were evaluated to determine whether case reports with ovarian teratoma were included. There were no language restrictions.

**Data extraction, collection, and analysis:** In the selected articles, a comprehensive data set was collected via a form designed for the present study. The form consisted of an Excel spreadsheet (Microsoft, Redmond, WA, United States), where each column captured a unique piece of information. When data were inadequate or insufficient for a definite piece of information, we recorded it as “not available”. Data of the individual patients were then pooled and analysed via the spreadsheet. A Microsoft Word document transposition of the form is provided as Supplementary material (Supplementary Tables 1-4).

**Statistical analysis**

GraphPad Prism 8 was used for statistical analyses.

**RESULTS**

**Case description**

Typical psychotic symptoms, and memory and consciousness disorders accompanied by seizures were observed in all six patients from this study. All patients showed positive signals in serum and cerebrospinal fluid samples for NMDAR and received operation and immunotherapy. Three patients underwent unilateral oophorocystectomy and the other three underwent unilateral oophorectomy through minimally invasive surgeries, including laparoscopic and single port laparoscopic surgeries. So far, no deaths have occurred. Two patients had recurrent psychotic symptoms while the remaining four had no mental symptoms or tumor recurrence during postoperative follow-up (Supplementary Table 1). A representative brain tissue pathology from one of the patients is shown in Figure 2.

**Systematic literature review**

In this paper, 155 cases in 130 case reports of anti-NMDAR encephalitis caused by ovarian teratoma were studied and analyzed (Supplementary Table 1).

**Epidemiological characteristics**

The number of papers and case reports has progressively increased since the 2007 publication of...
Hughes et al[19] (Table 1). In 2014, a systematic review of 173 cases of ovarian teratoma-associated anti-NMDAR encephalitis was published. Most articles containing case reports have been published in neurology or psychiatry journals. This is consistent with the results of the 2014 article[19].

As would be expected, there is a global disparity in terms of the available data from individual countries. The differences in national wealth/resources and the differences in health care play a major role in this disparity. It is further evident in the fact that there is not even a single report from Africa, to the best of the knowledge of authors. Further, there has been major advancements in the last few years as there was just a single case reported from China prior to the year 2014 whereas 27 cases have been reported after 2014 (Table 1)[19]. Thus, clearly the number of cases in China has increased significantly recently. Mean age of the patients was 25.0 ± 8.0 years with a median age of 25 years. The tumors were predominantly reported to be located on the right ovary. Immature teratomas or mature teratomas with immature foci were larger than dermoid cysts (Table 2).

Clinical findings

It is interesting to report that the clinical presentation of our six cases is very consistent with those reported earlier. Common symptoms were viral-like prodrome, including fever, headache or dizziness, nausea or vomiting, and general discomfort, along with abdominal pain, high blood pressure, and decreased sleep. Patients also reported severe psychiatric symptoms, speech dyskinesias, memory loss, seizures, reduced consciousness and sometimes orofacial dyskinesias, and progression to autonomic and respiratory instability.

This pooled study showed that prodrome with fever occurred in 19.0% of the patients, headache or dizziness in 26.4%, nausea or vomiting in 6.9%, other in 12.0%, no prodrome in 2.8%, and not specified in 32.9% (Figure 3A). The mean time from prodrome to psychosis was about 1 wk (Figure 3B). The clinical symptoms were psychiatric behavioral (22.8%), speech dyskinesias (pressured speech, verbal...
### Table 1 Year of publication and country of study of patients with anti-N-methyl-D-aspartate receptor encephalitis and ovarian teratoma

| Year of publication (No. of papers) | n (%) |
|------------------------------------|-------|
| 2014 (17)                          | 22 (14.2) |
| 2015 (19)                          | 20 (12.9) |
| 2016 (28)                          | 31 (20.0) |
| 2017 (32)                          | 38 (24.5) |
| 2018 (17)                          | 18 (11.6) |
| 2019 (17)                          | 26 (16.8) |
| Total (130)                        | 155 (100.0) |

| Country of birth or study | n (%) |
|---------------------------|-------|
| Asia: Japan-28; China-26; Korea-5; India-5; Taiwan-3; Thailand-2; Malaysia-1; Saudi Arabia-1; Israel-1 | 72 (46.5) |
| Australia: 5              | 5 (3.2) |
| Europe: Spain-12; United Kingdom-6; Italy-3; Netherlands-3; Poland-2; Russia-2; Germany-1; France-1; Hungary-1; Ireland-1; Croatia-1; Turkey-1; Espana-1; Romania-1; Osterreich-1 | 37 (23.9) |
| North-America: United States-36; Canada-3; Mexico-1 | 40 (25.8) |
| South-America: Ecuador-1   | 1 (0.6) |
| Total                     | 155 (100) |

### Table 2 Age of patients, histological type of ovarian teratoma, laterality of the affected ovary, and tumor size

| Variable | Histological type of ovarian teratoma | Total cases with teratoma |
|----------|---------------------------------------|----------------------------|
|          | Mature | Immature | Mature and immature | Not specified | 155 |
| Age (n)  | 130 | 14 | 2 | 9 | 155 |
| mean ± SD | 25.1 ± 8.3 | 24.8 ± 7.1 | 23.0 ± 0.0 | 25.2 ± 8.0 | 25.0 ± 8.0 |
| Median (min-max) | 25 (7-73) | 25 (9-38) | 23 (23-23) | 25 (14-36) | 25 (7-73) |
| Tumor location | | | | | |
| Right ovary | 56 (88.9) | 6 (9.5) | 0 | 1 (1.6) | 63 |
| Left ovary | 38 (86.4) | 6 (13.6) | 0 | 0 | 44 |
| Bilateral | 18 (85.7) | 0 | 2 (9.5) | 1 (4.8) | 21 |
| Not marked | 18 (66.7) | 2 (7.4) | 0 | 7 (25.9) | 27 |
| Total | | | | | 4.1 ± 3.3 (77) |
| Teratoma size (cm) | | | | | 5.7 (0.4-17) |

Among them, psychosomatic behavioral symptoms were the most common (Figure 4A) and more than half of the patients presented with three to five clinical symptoms (Figure 4C).

**Examinations**

Examinations included electroencephalography (EEG), colony-stimulating factor (CSF), brain magnetic resonance imaging (MRI), and IgG anti-GluN1 antibodies. More than half of the patients showed abnormal electroencephalogram, common for focal or diffuse slow or disorganized activity, epileptic activity, and extreme delta brush. More than half of the patients also showed abnormal cerebrospinal fluid, common for pleocytosis (> 5 white blood cells/mm³), and oligoclonal bands. About a third of the
cases had brain MRI abnormalities (Figure 5A). Among 155 cases, 145 were positive for antibody test, and 10 were not specified (Figure 5B).

**Final diagnosis**

Among the 150 surgical patients, 99 had full recovery and mild deficits, two had severe deficits, three died (including deep vein thrombosis and while receiving anticoagulation development of gastrointestinal bleeding in 1; severe septicemia in 2), and 47 had no prognosis data.
Treatment and prognosis

Treatment includes surgery and immunomodulation treatment. In 155 cases, 150 underwent surgical treatment, four did not undergo surgery, and one had no data on whether there was surgical treatment (Table 3). One patient with no information about surgical intervention, was in coma after 2 mo of follow-up. All four patients who did not undergo surgery died.

Outcome and follow-up

For the immunomodulation treatment, the combination of corticosteroid and intravenous immunoglobulin (IV Ig) and the combination of corticosteroid and IV Ig and plasmapheresis are common (Figure 5C).

DISCUSSION

We report here a series of six cases of ovarian teratoma-associated anti-NMDAR encephalitis from our hospital. Further, in the systematic review, we detailed cases of ovarian teratoma-associated anti-NMDAR encephalitis from the published literature. The pathogenesis of ovarian teratoma-associated anti-NMDAR encephalitis remains unclear. NMDARs originate from heteromers of NR1 and NR2 subunits. The NR1 subunit is known to bind to glycine while the NR2 subunit is known to bind to glutamate[20,21]. Antibodies in anti-NMDAR encephalitis patients cause a reversible titer-dependent loss of NMDARs[22], and they target an epitope on the NR1 subunit that resides in the hippocampal and frontotemporal regions[23,24]. Anti-NMDAR antibody production is related to the presence of tumors, mostly teratomas.

There seems to be a connection between the prodromal flu-like symptoms and the antibodies against NMDAR. Some researchers have emphasized the connection between viral (e.g., HSV) infection and injury of the blood–brain barrier. Therefore, analysis of CSF for the presence of NMDA receptor...
antibodies is important in patients with relapsing symptoms after HSE[25,26]. Human immunodeficiency virus and other neurotropic viruses (e.g., HSV) might also be a trigger for anti-NMDAR encephalitis[27]. Meningitis can induce transient blood-brain barrier disruption, which facilitates transmission of NMDAR autoantibodies to the CNS[25].

In a typical presentation of anti-NMDA receptor encephalitis, there is reported development of severe psychiatric symptoms, seizures, memory loss, and reduced consciousness. Often, there are additional manifestations such as orofacial dyskinesias and progression to autonomic and respiratory instability. Anti-NMDAR encephalitis is known to progress through five characteristic phases. The advanced stage is typically hallmarked by extreme autonomic instability with hyperthermia alternating with hypothermia, hypoventilation, fluctuating blood pressures, tachycardia, and even bradycardia as severe as asystole. Dysautonomia, sinus pauses, and asystole are likely caused by disruption in the balance between parasympathetic and sympathetic activity. Up to 90% of rhythm disturbances originate from sinus node abnormalities. Life-threatening cardiac dysrhythmia and cardiac arrest require urgent management[29,30]. Temporary pacing is occasionally required, but permanent pacing appears to be unnecessary[31].

In a case series of 100 anti-NMDA-R encephalitis patients, 69% of the patients were reported with autonomic instability and these patients required an average of 2 mo of ventilator support, with around 37% of the patients diagnosed with cardiac arrhythmias and four reported to be requiring pacemakers[7]. On the other hand, in a report that included 360 patients, two died because of sudden cardiac death while the reason for the death of one other patient was not fully determined[30].

A number of diagnostic tools are now available. These include serum analysis and CSF antibody against the NMDA receptor, EEG, analysis of CSF, and brain MRI. Additionally, the diagnosis of the tumor requires further tests such as transvaginal ultrasound, CT/MRI, and the evaluation of blood tumor markers. Pelvic ultrasound has also been employed to detect ovarian teratomas. CT scans can help identify calcification within the mass; however, MRI is much more accurate when making diagnoses for ovarian teratoma or the Mullerian duct anomalies. Further, whole-body PET/CT have consistently proven to be highly accurate when it comes to staging this disease. The diagnosis of anti-NMDA receptor encephalitis typically involves exclusion of other causes of encephalopathy. In case that the cause of a patient’s encephalopathy is not evident, attending physician needs to rule out anti-NMDA receptor encephalitis, particularly in patients with no reported psychiatric history. For diagnosis, lumbar puncture is required to collect and analyze CSF and then test for NR1 and NR2 using specific antibodies. A confirmed diagnosis is made if the anti-NMDAR antibodies are found in the CSF or in the serum. The diagnostic criteria have been described in the literature[27]. Based on the presence of clinical features consistent with the probable criteria, finding an adnexal mass, most likely a teratoma, upon finding anti-NMDAR antibodies in the CSF or serum, and after the exclusion of other possible etiologies, a diagnosis of anti-NMDA receptor encephalitis can be established.

Anti-NMDAR encephalitis had initially been described in young women with ovarian teratoma, but it is also common in women without tumor, in men, or in children[32]. Although not all patients presenting with NMDAR encephalitis are females with ovarian teratomas, the frequency of these patients mandates screening of females to rule out a causative tumor. The mainstays of treatment include immunomodulation and neoplasm removal targeting both symptomatic and causal factors[24].

Tumor removal is an effective treatment for anti-NMDAR encephalitis. Tumor removal in those with identifiable lesions leads to rapid clinical improvement. Even if none of the investigations are indicative of an ovarian teratoma, there still may be an occult ovarian teratoma[33]. In some cases, the teratoma is microscopic and only found following oophorectomy[34]. Tumor search and diagnosis are extremely important, and oophorectomy and oophorectomy are justified. Whether empiric exploratory laparotomy or laparoscopy and blind oophorectomies should be performed in patients with anti-NMDA receptor encephalitis without clinical evidence of a tumor is debatable. Because a laparoscopic examination for determining ovarian teratoma is less-invasive than laparotomy, trial laparoscopy may be acceptable for a treatment strategy if an ovarian tumor cannot be detected by various imaging tests.

Immunomodulation treatment consists of a first line therapy and a second line therapy. The first line therapy includes corticosteroid, IV Ig, and plasmapheresis used alone or in combination. Steroids, IV Ig, and plasmapheresis help reduce antibody titers. The second line therapy includes rituximab and

| Outcome type          | Tumor excision | Oomph | Surgery type not specified | No surgery | Not specified |
|-----------------------|----------------|-------|----------------------------|------------|---------------|
| Full recovery         | 37             | 27    | 7                          |            |               |
| Mild deficits         | 18             | 9     | 1                          |            |               |
| Severe deficits       | 1              | 1     | 1                          |            |               |
| Death                 | 1              | 2     | 4                          |            |               |
| Not specified         | 11             | 29    | 6                          |            |               |
cyclophosphamide, whether alone or in combination. Benzodiazepines and antipsychotics round out the pharmacotherapies employed in the treatment of seizures, psychosis, and behavioral dysfunction [31]. When the patient does not have a tumor, first-line therapy with IV Ig, methylprednisolone, and plasma exchange can be used in sequence or in combinations [35]. The second-line therapy with rituximab (against CD-20 B-lymphocytes) or cyclophosphamide can also be used [36]. It has been reported that almost half of the patients show significant improvement within a month of first line treatment and tumor removal. Further, second line therapy has been reported to be effective in up to two thirds of the patients who progressed after the first line of treatment. Thus, the prognosis of patients is generally very good once they have been administered either the first or, if needed, second line therapy [7].

In a systematic review of 100 cases of anti-NMDAR encephalitis, it was revealed that a better neurological outcome is achieved if surgical removal of the teratoma was performed quickly upon the onset of symptoms. This ensures much reduced probability of relapse and significantly improved recovery time [37]. Further, a systematic review of 174 cases of anti-NMDAR encephalitis revealed that even the small teratomas that contain nervous tissues, can result in severe complications which can be secondary to anti-NMDAR encephalitis [19].

Prognosis is generally poor for the patients, particularly those who are not attended to early in the disease. Generally, patients have a slow and incomplete recovery of neuropsychiatric sequelae in up to 3/4 of patients within an average of about 7 mo. It has been reported that a positive prognosis is linked to decreased anti-body titers. The one alarming statistic is that almost a quarter of patients are reported to relapse. The relapse is mostly reported within the first 2 years and there have been reports where relapse was associated with ovarian teratoma recurrence. On a bright side, relapses are often less severe. According to some estimates, 5%-7% of patients succumb to the disease within an average of 3.5 mo [7, 30].

CONCLUSION

Despite the emerging evidence, an association between ovarian teratoma and anti-NMDAR encephalitis is not fully realized. Anti-NMDAR encephalitis, a rare complication of ovarian teratoma, can be fatal. Therefore, its further understanding cannot be underestimated. Behavioral changes, acute psychiatric symptoms accompanied by seizures, and memory and consciousness disorders should be recognized, the possibility of anti-NMDAR encephalitis should be considered, and examinations for anti-NMDAR antibodies need to be completed to confirm the diagnosis as early as possible. Tumor location should be prioritized, once diagnosis is defined, and the tumor search should focus on the ovaries. If a tumor is detected (even with a benign appearance), it is recommended to remove the tumor as soon as possible. Choice of surgical procedure should be decided considering pathology, age, fertility desire, and patients’ requirements, and it should be ensured that tumors are completely removed during operation. Early use of corticosteroids and IgG-depleting strategies (IVIg or plasma exchange) may improve outcome. Postoperative follow-up is particularly important in case of recurrence.

ARTICLE HIGHLIGHTS

Research background
Anti-N-methyl-D-aspartate (NMDAR) encephalitis is a rare complication of ovarian teratoma that remains poorly understood.

Research motivation
Anti-NMDAR encephalitis can be fatal and the pathogenesis involving association with ovarian teratoma needs to be better understood in order to improve diagnosis as well as patient outcome.

Research objectives
We aimed to better understand anti-NMDAR encephalitis through a thorough examination of six patients enrolled in our hospital in addition to survey of the literature.

Research methods
We evaluated six patients enrolled in our hospital and, additionally, surveyed PubMed and Scopus to evaluate 155 cases of anti-NMDAR encephalitis in 130 reports. Focus was on diagnosis, treatments, and patient outcomes.

Research results
In our patient cohort, five of six patients fully recovered while the 6th patient recovered with deficits. In the surveyed literature, the majority of patients, particularly those with surgical intervention, had
positive outcome.

**Research conclusions**
Our evaluations revealed that surgical outcomes are favorable and early removal of tumor is critical. The importance of postoperative follow-up cannot be over-estimated.

**Research perspectives**
Early use of corticosteroids and IgG-depleting strategies may improve outcome. Postoperative follow-up is particularly important in case of recurrence.

**FOOTNOTES**

**Author contributions:** Li SJ and Yu MH contributed equally to this work; all authors contributed to the design and conduct of study, and approved the submission of this work for publication.

**Supported by** the Shanghai Municipal Commission of Health and Family Planning, No. 2017ZZ02016; the Funding from National Key Research and Development Program of China, No. 2021YFC2700400; the National Natural Science Foundation of China, No. 81974454; and the Shanghai Municipal Key Clinical Speciality, the Clinical Research Plan of SHDC, No. SHDC2020CR6009-002.

**Institutional review board statement:** The study was approved by the Ethic Committee of Shanghai Jiao Tong University.

**Informed consent statement:** Informed consent was obtained from all patients for participation in this study and the publication of results.

**Conflict-of-interest statement:** None of the authors have any conflict of interest to report.

**Data sharing statement:** Not available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** China

**ORCID number:** Shan-Ji Li 0000-0003-3628-516X; Min-Hua Yu 0000-0003-3628-516Y; Jie Cheng 0000-0003-3634-512X; Wen-Xin Bai 0000-0002-5523-662X; Wen Di 0000-0002-1190-0915.

**S-Editor:** Yan JP
**L-Editor:** Wang TQ
**P-Editor:** Yan JP

**REFERENCES**

1 Britton PN, Eastwood K, Paterson B, Durrheim DN, Dale RC, Cheng AC, Kenedi C, Brew BJ, Burrow J, Nagree Y, Leman P, Smith DW, Read K, Booy R, Jones CA; Australasian Society of Infectious Diseases (ASID); Australasian College of Emergency Medicine (ACEM); Australian and New Zealand Association of Neurologists (ANZAN); Public Health Association of Australia (PHAA). Consensus guidelines for the investigation and management of encephalitis in adults and children in Australia and New Zealand. Intern Med J 2015; 45: 563-576 [PMID: 25955462 DOI: 10.1111/imj.12749]

2 Leypoldt F, Armangue T, Dalmau J. Autoimmune encephalopathies. Ann Y Acad Sci 2015; 1338: 94-114 [PMID: 25315420 DOI: 10.1111/nyas.12553]

3 Guan HZ, Ren HT, Cui LY. Autoimmune Encephalitis: An Expanding Frontier of Neuroimmunology. Chin Med J (Engl) 2016; 129: 1122-1127 [PMID: 27098800 DOI: 10.4103/0366-6999.180514]

4 Titulaer MJ, McCracken L, GabiJlondo I, Armanagu T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Aribas N, Ryan-Florange N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12: 157-165 [PMID: 23290630 DOI: 10.1016/S1474-4422(12)70310-1]

5 Kayser MS, Dalmau J. Anti-NMDA Receptor Encephalitis in Psychiatry. Curr Psychiatry Rev 2011; 7: 189-193 [PMID: 24729779 DOI: 10.2174/157340011797183184]

6 Dalmau J, Tüzün E, Wu HY, Masjuan J, Ross J, Voloschon A, Bachrings JM, Shinazaki H, Koide R, King D, Mason W,
Gurvich A, Jensen N, Ostmeier K, Lühder F, Probst C, Martens H, Gillis M, Saher G, Assogna F, Spalletta G, Stöcker W, Barry H, Prüss H, Moscato EH, Hughes EG, Kalasinsky K, Lübke M, Spalletta G, Stöcker W, Dalmau J. Autoimmune encephalitis. Ann Neurol 2008; 63: 193-201 [PMID: 18505602 DOI: 10.1002/ana.21368]

Barry H, Byrne S, Barrett E, Murphy KC, Cotter DR. Anti-N-methyl-D-aspartate receptor encephalitis: review of clinical presentations, diagnosis and treatment. J Neuroimmunol 2010; 221: 146-156 [PMID: 20408034 DOI: 10.1016/j.jneuroim.2010.02.009]

Armangue T, Spatola M, Vlages A, Matts T, Gavara M, Lluís A, Sastre J, Gil R, Serrano-Aguirre F, Masjuan J, Brion J, Pardo LA, Sanchez-Leon A, Mato I, Pons-Solano J, Stöcker W, Dalmau J. Clinical, neuroimaging, and treatment features of a series of patients with anti-N-methyl-D-aspartate receptor encephalitis. Brain 2019; 142: 2619-2634 [PMID: 31269666 DOI: 10.1093/brain/awz264]

Birnbaum MD, Parenti D, Dichter MA, Rosenfeld MR, Lynch DR, Bataller L, Byrne S, Barrett E, Murphy KC, Cotter DR. Anti-N-methyl-D-aspartate receptor encephalitis: a systematic review of reported cases. J Neurosci 2010; 30: 8775-8786 [PMID: 20792444 DOI: 10.1523/JNEUROSCI.1633-10.2010]

Zandi MS, Irani SR, Follows G, Moody AM, Moloney P, Vincent A. Limbic encephalitis associated with antibodies to the NMDA receptor in Hodgkin lymphoma. Neurology 2009; 73: 2039-2040 [PMID: 19996080 DOI: 10.1212/WNL.0b013e3181e55c8]

Kendrick SJ, Styblinski E, St Clair J, Collier D, Rudge P, Marson AG. Anti-N-methyl-D-aspartate receptor antibody-related encephalitis: a systematic review of a small number of reports. J Neurol Neurosurg Psychiatry 2017; 88: 273-278 [PMID: 27199124 DOI: 10.1136/jnnp-2016-312357]

Laube B, Hirai H, Stürmer M, Betz H, Kuhse J. Molecular determinants of agonist discrimination by NMDA receptor subtypes: analysis of the glutamate binding site on the NR2B subunit. J Neurosci 2009; 29: 12483-12494 [PMID: 19759205 DOI: 10.1523/JNEUROSCI.3696-09.2009]

Armangue T, Geppert W, Thomsen M, Freytag M, Stübli A, Altmann M, Ameloot K, Bhatia S, Böhm B, Buus S, Cashman TM, Chen W, Clarey C, Coutinho D, Darbro M, Dichter MA, Dichter RB, Dichter MB, Diehl J, Eastwood A, Enzinger C, Feeley M, Ferguson M, Fidler A, Fialho J, Finke C, Gleichman AJ, Hughes EG, Lathrop SM, Lüders H, Lynch DR, Mody L, Nicholls D, Nickerson C, Nides H, Oster E, Perry V, Pitsillides C, Pitha J, Pollock C, Prusti G, Raber J, Reischl U, Riederer P, Richens A, Rioufol G, Rizzuto R, Robert C, Romagnani S, Rudge P, Sabatowski R, Schenck MH, Schiffer H, Schoieder I, Schomer D, Schott K, Setzler M, Shapira J, Silverstein N, Sinha S, Smith A, Snow P, Stafstrom CE, Stein J, Straus SE, Stürmer M, Surmeier DJ, Tóth B, Towne B, Trinka E, Ulieru M, Ulmer C, van den Bergh H, van den Heuvel SO, van Gelderen P, Weidner N, Wider M, Woodruff TP, Zaborszky L, Zarranz JJ, Zuccato C, Zühlke J, Zürcher C. Anti-NMDA receptor encephalitis: a collaborative project of the European Federation of Neurological Societies and the International League Against Epilepsy. Lancet Neurol 2011; 10: 272-282 [PMID: 21204380 DOI: 10.1016/S1474-4422(11)70031-7]

Iizuka T, Nokura K, Okamura H, Yamamoto H, Okawara Y, Koga H, Osawa H, Sakai K. Reversible limbic encephalitis caused by ovarian teratoma. Acta Neurol Scand 2005; 112: 388-390 [PMID: 16019012 DOI: 10.1111/j.1600-0404.2004.00469.x]

Okamura H, Oomori N, Uchitomi Y. An acutely confused 15-year-old girl. Lancet 1997; 350: 488 [PMID: 9274586 DOI: 10.1016/S0140-6736(97)00628-9]

Dai Y, Zhang J, Ren H, Zhou X, Chen J, Cui L, Lang J, Guan H, Sun D. Surgical outcomes in patients with anti-N-methyl-D-aspartate receptor encephalitis with ovarian teratoma. Am J Obstet Gynecol 2019; 221: 845.e1-845.e10 [PMID: 31126109 DOI: 10.1016/j.ajog.2019.05.026]

Acién P, Acién M, Ruiz-Macías E, Martín-Estefanía C. Ovarian teratoma-associated anti-NMDAR encephalitis: a systematic review of reported cases. Orphanet J Rare Dis 2014; 9: 157 [PMID: 25312434 DOI: 10.1186/s13023-014-0157-x]

Kendrick SJ, Lynch DR, Pritchett DB. Characterization of glutamate binding sites in receptors assembled from transfected NMDA receptor subunits. J Neurochem 1996; 67: 608-616 [PMID: 8764586 DOI: 10.1002/jnc.4706702006]

Laube B, Hirai H, Sturgess M, Betz H, Kuhse J. Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron 1997; 18: 493-503 [PMID: 9115742 DOI: 10.1016/0896-6273(97)00129-0]

Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou T, Tsou R, Parsons JD, Lynch DR, Dalmau J, Barlow JD. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neuropathol Exp Neurol 2010; 69: 876-875 [PMID: 20472647 DOI: 10.1523/JNEUROSCI.0167-10.2010]
depends on blood-brain barrier integrity. *Mol Psychiatry* 2014; 19: 1143-1149 [PMID: 23999527 DOI: 10.1038/mp.2013.110]

29 **Inayat F**, Hung Pinto WA, Ahmad S, Hussain A, Ullah W. Anti-N-methyl-D-aspartate Receptor Encephalitis Associated with Ictal Torsades de Pointes and Cardiac Arrest. *Cureus* 2019; 11: e4837 [PMID: 31403022 DOI: 10.7759/cureus.4837]

30 **Nazif TM**, Vázquez J, Honig LS, Dizon JM. Anti-N-methyl-D-aspartate receptor encephalitis: an emerging cause of centrally mediated sinus node dysfunction. *European* 2012; 14: 1188-1194 [PMID: 22345374 DOI: 10.1093/europace/eus014]

31 **Dalmau J**, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. *Lancet Neurol* 2011; 10: 63-74 [PMID: 21163445 DOI: 10.1016/S1474-4422(10)70253-2]

32 **Prüss H**, Dalmau J, Arlot V, Wandinger KP. [Anti-NMDA-receptor encephalitis. An interdisciplinary clinical picture]. *Nervenarzt* 2010; 81: 396, 398, 400, passim [PMID: 20119656 DOI: 10.1007/s00115-009-2908-9]

33 **Boeck AL**, Logemann F, Krauß T, Hussein K, Bültmann E, Trebst C, Stangel M. Ovarectomy despite Negative Imaging in Anti-NMDA Receptor Encephalitis: Effective Even Late. *Case Rep Neurol Med* 2013; 2013: 843192 [PMID: 23533859 DOI: 10.1155/2013/843192]

34 **Raynor G**, Bader C, Srikanth M, Kroll D, Gutheil T, Berkowitz A. Psychosis Secondary to Anti-N-methyl-D-Aspartate Receptor Encephalitis. *Harv Rev Psychiatry* 2016; 24: 229-237 [PMID: 27148913 DOI: 10.1097/HRP.0000000000000118]

35 **Pham HP**, Daniel-Johnson JA, Stotler BA, Stephens H, Schwartz J. Therapeutic plasma exchange for the treatment of anti-NMDA receptor encephalitis. *J Clin Apher* 2011; 26: 320-325 [PMID: 21898576 DOI: 10.1002/jca.20311]

36 **Kashyape P**, Taylor E, Ng J, Krishnakumar D, Kirkham F, Whitney A. Successful treatment of two paediatric cases of anti-NMDA receptor encephalitis with cyclophosphamide: the need for early aggressive immunotherapy in tumour negative paediatric patients. *Eur J Paediatr Neurol* 2012; 16: 74-78 [PMID: 21831679 DOI: 10.1016/j.ejpn.2011.07.005]

37 **Tumbi A**, Gilani A, Scarff JR, Kaur G, Lippmann S. Anti-N-methyl-D encephalitis. *Innov Clin Neurosci* 2011; 8: 24-25 [PMID: 22010062]
